Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. T…
Biotechnology
US, Waltham [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | 21.77 | 3.77 | 3.10 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | -41.37 | -1.68 | 2.87 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 35.17 | 2.17 | 1.60 | |
| Cash | -7.49 | 2.72 | 2.94 | |
| Capex | -204.09 | < 0.005 | < 0.005 | |
| Free Cash Flow | -34.13 | -1.08 | -0.81 | |
| Revenue | 16.08 | 1.40 | 1.21 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | 1.87 | 0.88 | 0.86 | |
| Operating Margin | 37.60 | -0.36 | -0.58 | |
| ROA | 28.90 | -0.08 | -0.11 | |
| ROE | 45.30 | -0.25 | -0.46 | |
| ROIC | 69.02 | -0.09 | -0.29 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of APLS is permitted for members.
5
Growth
The "Growth Entry" for the Focus of APLS is permitted for members.
6
Leverage & Liquidity